argenx (NASDAQ:ARGX) Sees Large Volume Increase - Should You Buy?

argenx SE (NASDAQ:ARGX - Get Free Report) saw unusually-strong trading volume on Tuesday . Approximately 178,130 shares traded hands during trading, a decline of 42% from the previous session's volume of 307,727 shares.The stock last traded at $600.37 and had previously closed at $606.39.

Analyst Upgrades and Downgrades

ARGX has been the subject of several research analyst reports. Guggenheim increased their target price on argenx from $775.00 to $1,100.00 and gave the company a "buy" rating in a research note on Monday, March 10th. Robert W. Baird boosted their target price on shares of argenx from $650.00 to $680.00 and gave the stock a "neutral" rating in a research report on Tuesday, March 4th. Deutsche Bank Aktiengesellschaft raised shares of argenx from a "sell" rating to a "hold" rating in a research report on Wednesday, March 12th. JMP Securities boosted their price objective on argenx from $606.00 to $696.00 and gave the company a "market outperform" rating in a report on Tuesday, January 14th. Finally, Citigroup increased their target price on argenx from $681.00 to $796.00 and gave the stock a "buy" rating in a report on Thursday. Three equities research analysts have rated the stock with a hold rating, nineteen have given a buy rating and one has given a strong buy rating to the company's stock. According to MarketBeat.com, the company has a consensus rating of "Moderate Buy" and a consensus price target of $699.28.

argenx Stock Performance

The stock has a 50 day moving average price of $602.53 and a 200 day moving average price of $605.93. The company has a market cap of $36.23 billion, a P/E ratio of -677.50 and a beta of 0.60.

argenx (NASDAQ:ARGX - Get Free Report) last issued its quarterly earnings results on Thursday, February 27th. The company reported $1.58 earnings per share for the quarter, beating analysts' consensus estimates of $0.98 by $0.60. The company had revenue of $761.22 million during the quarter, compared to the consensus estimate of $678.52 million. argenx had a negative net margin of 2.11% and a negative return on equity of 1.45%. As a group, equities research analysts predict that argenx SE will post 3.13 earnings per share for the current year.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of the stock. GeoWealth Management LLC grew its holdings in shares of argenx by 56.3% in the 4th quarter. GeoWealth Management LLC now owns 50 shares of the company's stock worth $31,000 after acquiring an additional 18 shares during the last quarter. Rakuten Securities Inc. raised its holdings in argenx by 56.4% during the 1st quarter. Rakuten Securities Inc. now owns 61 shares of the company's stock worth $36,000 after buying an additional 22 shares during the period. Whipplewood Advisors LLC purchased a new stake in argenx during the fourth quarter valued at about $37,000. Global Retirement Partners LLC boosted its holdings in shares of argenx by 369.2% in the fourth quarter. Global Retirement Partners LLC now owns 61 shares of the company's stock worth $38,000 after buying an additional 48 shares during the period. Finally, FIL Ltd purchased a new position in shares of argenx in the fourth quarter worth approximately $38,000. Institutional investors own 60.32% of the company's stock.

About argenx

argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren's syndrome, post-covid postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, anca-associated vasculitis, and antibody mediated rejection; ENHANZE SC; Empasiprubart for multifocal motor neuropath, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis.